Shares in this article
Indices in this article
EVOTEC announced on Monday in the Hanseatic city that the group had submitted the necessary documents for an upcoming offer of so-called American Depository Shares (ADS) to the responsible stock exchange regulator SEC. The company, which is listed in the MDAX and TecDAX, is planning a secondary listing on the NASDAQ technology exchange. Assuming the approval of the SEC, the initial listing is expected for the second half of the year, but the final number of ADSs to be offered and the offer price have not yet been determined. The new shares are to be issued from the authorized capital.
EVOTEC was already listed on NASDAQ in the past decade as part of the takeover of the US biotech company Renovis, but then voluntarily withdrew from there in order to concentrate more on the domestic financial market. In addition, a second note is also a cost factor. However, Anglo-Saxon investors are seen as more open-minded and more willing to invest in the biotech industry, which is why, for example, the industry members MorphoSys and QIAGEN, which are also listed in the MDax, have a secondary listing in the USA.
The Mainz company BioNTech, known for its corona vaccine, even has its main listing on NASDAQ.
EVOTEC shares are then temporarily 3.23 percent cheaper via XETRA to 33.85 euros.
More news about EVOTEC SE
Image Sources: REMY GABALDA / AFP / Getty Images